Previous 10 | Next 10 |
Alcon (NYSE:ALC): Q3 Non-GAAP EPS of $0.54 beats by $0.03; GAAP EPS of $0.00 misses by $0.15. Revenue of $2.08B (+14.3% Y/Y) beats by $30M. Shares -2%. Press Release For further details see: Alcon EPS beats by $0.03, beats on revenue
Third quarter sales of $2.1 billion, up 15% or 14% constant currency Continued growth in all Surgical and Vision Care categories versus 2020, driven by innovation, commercial execution and market recovery Nine months cash from operations of $958 million and...
Alcon (NYSE:ALC) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is $0.50 (+28.2% Y/Y) and the consensus Revenue Estimate is $2.04B (+12.1% Y/Y). Over the last 2 years, ALC has beaten EPS estimates 75% of the time and has b...
SMART Solutions by Alcon, a digital platform uniquely designed for ophthalmology, builds on Alcon leadership in image-guided clinic to OR connectivity through cloud-based planning and surgical equipment Installs of first application, SMARTCataract, are underway with U.S. cus...
Alcon (NYSE:ALC) has acquired Ivantis, developer and manufacturer of the novel Hydrus Microstent, a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery. The deal involves $475M in up...
Expands Alcon’s leading surgical portfolio and leverages the company’s commercial execution expertise Strong safety and efficacy profile evidenced by five-year study on Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device Indicated to ...
TOTAL30 contact lenses to be showcased at the conference through in-booth lens try-on, an exclusive launch event for eye care professionals, scientific data presentations and more Numerous clinical presentations to affirm the efficacy of Alcon’s portfolio of contact lenses ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy was held back by weakness among our emerging...
Alcon associates across 43 global sites take the Steps for Sight challenge, raising funds to support organizations improving access to quality eye care Alcon Geneva associates will dedicate the day to learning more about the importance of eye health, including onsite vision ...
With 62 recent IPOs becoming part of The Russell 2000 small-cap index following its Q3 recalibrations, we highlight the healthcare stocks among the new entrants. The below discussion is a follow-up to the previous article on newly IPO’d healthcare constituents in the Index. R...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...